In order to guide and standardize the clinical trials of anti-HIV new drugs and promote the research and development of innovative drugs, the CDE has formulated the Technical Guidance for Clinical Trials of Anti-HIV Infectious Drugs, which was issued and implemented on October 12, 2021 upon the review and approval by the National Medical Products Administration.